GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (NAS:IMGN) » Definitions » Accounts Receivable

Immunogen (Immunogen) Accounts Receivable : $130.7 Mil (As of Sep. 2023)


View and export this data going back to 1989. Start your Free Trial

What is Immunogen Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Immunogen's accounts receivables for the quarter that ended in Sep. 2023 was $130.7 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Immunogen's Days Sales Outstanding for the quarter that ended in Sep. 2023 was 105.14.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Immunogen's Net-Net Working Capital per share for the quarter that ended in Sep. 2023 was $1.68.


Immunogen Accounts Receivable Historical Data

The historical data trend for Immunogen's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Accounts Receivable Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 7.50 0.04 4.47 12.60

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 12.60 27.34 75.36 130.69

Immunogen Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Immunogen Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Immunogen's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=130.694/113.425*91
=105.14

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Immunogen's accounts receivable are only considered to be worth 75% of book value:

Immunogen's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(605.535+0.75 * 130.694+0.5 * 5.495-260.505
-0-0)/265.842
=1.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Immunogen Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Immunogen's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunogen (Immunogen) Business Description

Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.
Executives
Theresa Wingrove officer: VP of Regulatory Affairs IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Renee Lentini officer: V.P.-Fin., Prin. Acctg. Off. 830 WINTER STREET, WALTHAM MA 02451
Stacy Ann Coen officer: Chief Business Officer 11 RUSH POND RD, LAKEVILLE MA 02347
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Lauren White officer: SVP, CFO and PFO C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Mark J Enyedy director, officer: Chief Executive Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Isabel Kalofonos officer: SVP & CHIEF COMMERCIAL OFFICER C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Michael Vasconcelles officer: EVP R&D & MEDICAL AFFAIRS C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140
Daniel Char officer: SVP & CHIEF LEGAL OFFICER C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Kristen Harrington-smith officer: SVP & Chief Commercial Officer C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Tracey L Mccain director C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
David G Foster officer: V.P.-Fin., Prin. Acctg. Off. C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Susan Altschuller officer: SVP and CFO 45 TENNYSON ST., SOMERVILLE MA 02145
Craig Barrows officer: Vice-President,General Counsel C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451